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Abstract
Background:  Stress urinary incontinence is a common condition affecting approximately 20% of adult women causing
substantial individual (quality of life) and economic (119 million Euro/year spent on incontinence pads in the Netherlands)
burden. Pelvic floor muscle training (PFMT) is regarded as first line treatment, but only 15-25% of women will be completely
cured. Approximately 65% will report that their condition improved, but long term adherence to treatment is problematic. In
addition, at longer term (2-15 years) follow-up 30-50% of patients will end up having surgery. From 1996 a minimal invasive
surgical procedure, the Tension-free Vaginal Tape (TVT) has rapidly become the gold standard in surgical treatment of stress
urinary incontinence. With TVT 65-95% of women are cured. However, approximately 3-6% of women will develop symptoms
of an overactive bladder, resulting in reduced quality of life. Because of its efficacy the TVT appears to be preferable over PFMT
but both treatments and their costs have not been compared head-to-head in a randomised clinical trial.
Methods/Design: A multi-centre randomised controlled trial will be performed for women between 35 - 80 years old with
moderate to severe, predominantly stress, urinary incontinence, who have not received specialised PFMT or previous anti-
incontinence surgery. Women will be assigned to either PFMT by a specialised physiotherapist for a standard of 9-18 session in
a period of 6 months, or TVT(O) surgery. The main endpoint of the study is the subjective improvement of urinary incontinence.
As secondary outcome the objective cure will be assessed from history and clinical parameters. Subjective improvement in
quality of life will be measured by generic (EQ-5D) and disease-specific (Urinary Distress Inventory and Incontinence Impact
Questionnaire) quality of life instruments. The economical endpoint is short term (1 year) incremental cost-effectiveness in
terms of costs per additional year free of urinary incontinence and costs per Quality Adjusted Life Years (QALY) gained. Finally,
treatment strategy and patient characteristics will be combined in a prediction model, to allow for individual treatment decisions
in future patients. Four hundred female patients will be recruited from over 30 hospitals in the Netherlands
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Background
Urinary incontinence is a common problem among adult
women, with an estimated overall prevalence of 40% and
between 6-10% of women with severe incontinence.[1]
Stress urinary incontinence is the predominant type of
incontinence affecting approximately 50% of incontinent
women. Thus, 20% of adult women will experience stress
urinary incontinence. The severity of urinary incontinence
is often expressed in the number of incontinence epi-
sodes/week, where 7-14 episodes/week is considered as
moderate and more than 14 episodes/week as severe
incontinence.[1]
In addition, urinary incontinence is known to have a neg-
ative impact on quality of life and the economical costs
related to it are substantial. These patient-centred and eco-
nomical outcomes are important. For the treatment of
stress urinary incontinence there are two options: pelvic
floor muscle training (PFMT) and surgery. PFMT is cur-
rently advised as primary treatment, because it is statisti-
cally significant more likely to improve incontinence
symptoms as compared to no or sham physiotherapy (OR
1.42, 95%CI 1.28-1.58).[2] Approximately 65% of
women treated with PFMT experience improvement of
their incontinence. However, a 100% cure rate (no incon-
tinence episodes) is recorded in only 15 to 28% of
women.[3,4] In addition to the low percentage of objec-
tive cure, the long-term efficacy of PFMT is under debate.
After a 3-15 year follow-up, 25-50% of women primarily
treated with PFMT have undergone surgery.[5-7] This can
be due to lack of persistent efficacy, but may also be
related to lack of compliance with the physiotherapy pro-
gram.
In the past decade, surgery for stress incontinence has
made a huge progression with the introduction of mini-
mally invasive surgical techniques. The Tension-free Vagi-
nal Tape (TVT) and Tension-free Vaginal Tape Obturator
(TVT-O) are the most frequently performed procedures. In
both cases, a small incision is made under the mid urethra
through which a polypropylene mesh is placed without
tension under the urethra. If abdominal pressure
increases, the urethra is compressed to the tape and conti-
nence is restored. An advantage of these procedures is that
they can be performed in day-care.[8] After a TVT(O) pro-
cedure approximately 66% of women are completely
cured (100% dry) and 80-95% of women show an
improvement.[9] Furthermore, this effect seems to be
longstanding. However, although minimal invasive, stress
incontinence surgery carries a risk of complications. Major
complications are extremely rare with an incidence of
0.007% for bowel perforation and 0.012% for vascular
injury.[8] The most common complication of bladder
perforation during the procedure (approximately 3-6%
for TVT and below 1% for TVT-O is easily recognized dur-
ing the procedure itself and carries no long-term morbid-
ity. Adverse outcome of surgery in terms of the
development of new symptoms may be a bigger concern.
Voiding difficulties and symptoms of an overactive blad-
der are reported in 6% of cases.[9]
In the Netherlands, women are usually seen by the general
practitioner (GP) first. The GP Dutch guidelines (revised
version 2006) on stress incontinence advocate to either
start treatment with PFMT with instructions of the GP, or
to refer to a specialised physiotherapist. In 2001 the
Health Counsel reported that only 1.6% of women were
referred to a physiotherapist.[10] Thus, the majority of
incontinent women were not referred to specialised ther-
apy. Treatment by the GP consists of giving verbal and
written instructions (as is described in their guideline)
how to contract and train the pelvic floor, with first revi-
sion after 3 months. This is clearly different from the
weekly, individual sessions given by a specialised (bio-
feedback) physiotherapist. If treatment by the GP fails, it
is advocated to refer the woman for specialised PFMT
physiotherapy. This is the group of women where our
study aims at.
The main objective of our study is to answer the question
whether it is more (cost) effective to refer for specialised
PFMT or for TVT(O) surgery after the standard initial
instruction and training given by the GP has failed.
Primary surgery in this group of patients may be cost-
effective when compared to PFMT as its cure rate is higher.
A comparison of both strategies has been performed in a
small sample of patients comparing abdominal Burch sur-
gical procedure versus PFMT.[11] Although this single
study concluded that primary surgery was preferable, the
design and power did not meet the standards to provide
sufficient scientific evidence. Finally, it is unclear which
factors are associated with success or failure of PFMT and
TVT. After identification of these factors a prediction
model can be built that can further individualize treat-
ment. In addition to our cost-effectiveness analyses we
aim to develop such a prediction model.
Methods
Study Aims
The primary aim of the PORTRET study is to compare the
clinical and cost-effectiveness of PFMT versus the TVT/
TVT-O procedure as treatment for moderate to severe
stress urinary incontinence.
Study design and setting
The PORTRET study is a multidisciplinary, multicentre
non-blinded therapeutic randomised controlled trial.
Randomisation will be performed centrally with compu-
terised randomisation tables. The two trial arms are PFMTBMC Women's Health 2009, 9:24 http://www.biomedcentral.com/1472-6874/9/24
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by a specialised physiotherapist and a surgical interven-
tion with the TVT or TVT-O. Recent data show that both
the TVT and TVT-O are equally effective.[12,13] For obvi-
ous reasons blinding of treatment between PFMT and sur-
gery will not be possible. To reflect daily practice as close
as possible the assessment of costs will start directly after
randomisation. We expect that the maximum effect of
PFMT will be reached within 3-6 months. To account for
possible changes in symptoms and changes in costs dur-
ing this period, cost and symptom assessments are made
every two months by means of a telephone administered
questionnaire during the first 4 months. After that an
assessment at 6, 12 and 18 months is performed. From lit-
erature, one of the predictive factors for the efficacy of
treatment is the severity of incontinence at baseline.
Therefore, we will introduce stratification by severity into
the randomisation. We will stratify according to the sever-
ity (moderate or severe) as established by the Sandvik
index [see table 1]. [14] The flowchart and study design
are presented in figure 1 and table 2
Ethical consideration
The study has been approved for by the medical ethical
review commission of the Universitary Medical Centre
Utrecht (METC UMCU 07/278). Full medical ethical
approval has been obtained on 05-02-2008.
Identification and determination of eligible patients
All women aged 35-80 years whom present with sympto-
matic moderate to severe, according to the Sandvik sever-
ity index (≥ 3) [14], predominant stress urinary
incontinence, will be considered for inclusion. They
should present themselves with the problem of inconti-
nence to their general practitioner, gynaecologist or urol-
Flow chart Figure 1
Flow chart.
Women with predominant moderate to severe 
stress urinary incontinence whom seek treatment 
Diagnostic work-up 
Fulfill all in- and exclusion criteria 
Randomisation, stratified by severity 
Blocks of 4 
N = 400 
Pelvic Floor 
Muscle Training 
N = 200 
TVT(O) 
Surgery 
N = 200 
Follow up after complete 
treatment at 
6,12 and 18 months 
Follow up after 
complete treatment at 
6,12 and 18 months 
At 0, 2 and 4 months training 
interval 
Compliance and additional 
cost measurements
At 0, 2 and 4 months interval 
Additional cost measurementsBMC Women's Health 2009, 9:24 http://www.biomedcentral.com/1472-6874/9/24
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ogist. They should not have already been referred for
specialised pelvic floor muscle training.
The predominance of SUI is assessed with the Stress/Urge
Incontinence Questionnaire (S/UIQ). Two questions are
asked. "How many times in the last seven days have you
had an accidental leakage of urine onto your clothing,
underwear, or pad?".
- During an activity such as coughing, sneezing, laughing,
running, exercising or lifting? Symptom of stress urinary
incontinence (SUI).
- With a sudden strong need to pass water that you could
not reach the toilet in time? Symptom of urge urinary
incontinence (UUI).
For predominant stress urinary incontinence the number
of SUI events should outnumber the number of UUI.
Urodynamic testing will not be used in this study, unless
the physician decides this is necessary. Its sensitivity, spe-
cificity and predictive value for diagnosing and predicting
outcome in female urinary incontinence has not been
proved.[15] So no exclusion criteria will be based on uro-
dynamic assessments (if performed).
SUI must have been demonstrated on physical examina-
tion or on urodynamic assessment if performed. Patients
will be excluded in case of previous incontinence surgery,
pelvic organ prolaps stadium 2 or higher according to
POP-Q classification or in case of residual post voiding
bladder volume of more than 100 ml on catheterisation
or ultrasound (Bladderscan®)
Study Interventions
After obtaining informed consent, eligible women will be
assigned to either PFMT by a specialised physiotherapist
for a standard of 9-18 sessions in a period of 6 months, or
TVT(O) surgery.
Randomisation
After checking the inclusion criteria an eligible patient is
asked if she might be willing to participate and will receive
written and verbal information about the study. A new
appointment with the research nurse will be made. After
an interval of one week the research nurse will ask if the
patients wants to participate in the study and the exclu-
sion criteria are checked. This will be done by the research
nurse, not by the medical specialist him/herself. If an eli-
gible patient wants to cooperate she is asked to sign the
informed consent. When in- and exclusion criteria are
met, randomisation will take place. Study inclusion and
exclusion criteria are presented in figure 2.
Randomisation will be performed with the use of compu-
terised randomisation tables. The randomisation will be
stratified according to the severity of incontinence (mod-
erate or severe as established by the Sandvik index. For
obvious reasons (surgery versus conservative treatment)
both the randomisation outcome and the personal
involved in outcome assessment cannot be blinded.
Patient follow-up procedures
Patients will be followed from the start of primary therapy
until 18 months later. Follow up will consist of various
elements
In all patients the next items will be recorded at inclusion:
1. Baseline characteristics
2. History and clinical examination
3. 48 h-bladder (voiding and incontinence) diary
4. 24 h-padtest
5. Validated Quality of Life questionnaires (Urinary
Distress Inventory, Incontinence Impact Question-
naire, Euroqol 5D, patient global impression of sever-
ity/improvement)
6. Uroflow measurement including post void residual
volume
7. Cost-analysis questionnaire
The onset of primary therapy, either TVT(O) in the surgery
arm of the study or PFMT in the physiotherapy arm of the
study will be T = 0
In case of surgery, the patient will receive the standard care
associated with the pre-, per- and postoperative standards
of the participating hospital. She will visit the hospital
after surgery at 6 weeks, 6, 12 and 18 months. Question-
naires will be handed out at these visits containing the
Table 1: Sandvik Index
SANDVIK INDEX Quantity of urine loss
1 = drops 2 = more than drops
Episodes
1 = < 1 time a month 1 2
2 = 1 to more times a month 2 4
3 = 1 to more times a week 3 6
4 = daily 4 8BMC Women's Health 2009, 9:24 http://www.biomedcentral.com/1472-6874/9/24
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items mentioned above. Furthermore, special attention
will be given with respect to extra visits to the general prac-
tioner, physiotherapist or specialist visits in relation to the
surgical procedure that might have taken place and phys-
ical examination will be performed. Costs associated with
incontinence and therapy will also be assessed with tele-
phone administered questionnaire at 2 and 4 months fol-
low-up. Women who are enrolled for PFMT will be
followed-up according to the same schedule besides the 6
weeks post operative check-up.
Patient outcome measures
This study will compare the clinical and cost-effectiveness
of PFMT versus the TVT/TVT-O procedure as treatment for
moderate to severe stress urinary incontinence.
Primary outcome: Subjective improvement of urinary
incontinence
Secondary outcome(s):
Table 2: Study Design Schedule
Baseline visit Randomisation study entry 2, 4 months* 6 months visit 12 months visit 18 months visit
Patient characteristics X Checking Inclusion & 
Exclusion Criteria
Gynaecologic 
examination
X X
Assessment of pelvic 
floor functioning
XX X
48 hour bladder 
diary
XX X
Flow X X X
Residual volume X X X
Stress test X X X
Sandvik index X X X
24 hour pad test X X
Global Impression 
of severity
XX X X X
Global Impression of 
improvement
XX X X
EQ-5D X X X X
UDI X X X X
IIQ X X X X
Costs assessment* X X X X X
Compliance with 
treatment #
XX
Complications of 
surgery#
X
* After randomisation costs assessment will be made for both groups at 2 and 4 months in order to account for changes
occurring during progression of (PFMT) treatment.
# Compliance is measured only for the PFMT group in order to assure proper training, complications are only related to surgery.BMC Women's Health 2009, 9:24 http://www.biomedcentral.com/1472-6874/9/24
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1. Complete cure on objective and subjective parameters.
2. Subjective improvement in generic and disease-specific
quality of life.
3. Complications and de novo urogenital symptoms.
4. The incremental cost-effectiveness of TVT as compared
to PFMT, accounting for direct and indirect costs parame-
ters.
5. Development of a prediction model for successful treat-
ment, with the therapy given (PFMT or TVT) as independ-
ent variable in the model.
Sample size considerations
Literature shows a subjective improvement of inconti-
nence after PFMT up to 65%, and a subjective improve-
ment after TVT(O) of at least 80%. In order to detect this
difference with a power of 0.9 and an alpha of 0.05, we
need 200 women in each trial arm. For our primary out-
come parameter, total cure of incontinence, the expected
difference between both arms is much larger: 28% cure
after PFMT, and 65% cure after TVT. The 200 women in
each treatment arm will be largely sufficient to assess a sta-
tistically significant difference in this secondary outcome.
Sample size calculation for the prediction models is based
on the number of successes (or failures). For each predic-
tor in the model we need 10-15 successes. Our pre-
defined prediction model consists of 5 predictors and the
interaction terms with treatment. Our total sample size
will exist of 400 women. The expected number of suc-
cesses (cure) of the PFMT group is 30 (15% of 200)
women, the number of women cured after TVT is an esti-
mated 130 (65% of 200 women). So the total number of
complete cure is an estimated 160 women, with 240
women being not completely cured. These figures are suf-
ficient for modelling up to 10-12 predefined possible pre-
dictors of cure. With respect to subjective improvement an
estimated total of 290 women will show subjective
improvement as measured with the Patient Global
Impression of Improvement (PGI-I) questionnaire (65%
of 200 women with PFMT plus 80% of 200 women in TVT
group). Thus, 110 women can be considered failures.
Again, this also allows us to make a prediction model for
improvement with the predefined predictors. Therefore
the study sample will also be amply sufficient for predic-
tion purposes.
Economic evaluation
In accordance with the primary aim of the clinical trial,
the primary outcome for the economic evaluation will be
the number of women with satisfactory results, i.e., sub-
jectively improved, at 6, 12 and 18 months. During the
period that women allocated to PFMT follow their train-
ing program, women whom underwent TVT(O) may
already experience a period with satisfactory outcome.
Study inclusion and exclusion criteria Figure 2
Study inclusion and exclusion criteria.
Study inclusion and exclusion criteria
Inclusion criteria
• Women aged 35-80 years  
• Symptoms of moderate to severe, predominant stress urinary 
incontinence. 
• Confirmation of stress urinary incontinence during gynaecological
examination and /or urodynamics
• Sandvik index ≥ 3
Exclusion criteria
• Post voiding bladder volume > 100 ml, on bladder catheterisation or 
ultrasound (Bladderscan®)
• History of anti-incontinence surgery
• Specialised Pelvic Floor Muscle Training (PFMT) in the previous 6 months
• Genital prolapse Stage 2 or more (POP-Q classification)
• Patients desire for future pregnancy and childbirth
• Co-morbidity which is associated with increased surgical risks
• History of recurrent lower urinary tract infection (> 3 times/year)
• Insufficient knowledge or understanding of the Dutch language
• The use of medication that may affect bladder function.
• History of or current major psychiatric illness.
• History of chronic neurological disease.BMC Women's Health 2009, 9:24 http://www.biomedcentral.com/1472-6874/9/24
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This time aspect will be accounted for by estimating and
comparing person time with satisfactory results.
Health related quality of life (HRQoL) is considered a
important outcome. In addition to the disease specific
questionnaires (UDI and IIQ), two global questions,
Patient Global Impression of Severity and Patient Global
Impression of Improvement, (PGI-S and PGI-I), and a
generic questionnaire, Euroqol 5D (EQ-5D) will be filled
out at baseline and at regular intervals up to twelve
months after completion of treatment. Using the EQ5D
the outcome in terms of quality adjusted life years
(QALYs) can be estimated. The effects observed by means
of the disease specific questionnaire will be reported sep-
arately. [16-18]
Costs of the strategies directly TVT(O) as well as PFMT will
be estimated using a societal perspective. Accordingly,
direct medical costs will be based on the actual costs of the
personnel and other resources used such as incontinence
pads. Unit costs will be based on a specific costing study
conducted in the hospital setting and the primary care set-
ting. Where available unit costs will be based on the
standard prices published in the current guidelines. Also,
as PFMT is much more time consuming for the patients
the costs associated to sick leave at work will be estimated
using the friction cost method. The hours women spend
on travel and training etc. will be assessed by question-
naires and subsequently valued.
COST-EFFECTIVENESS
The incremental costs per QALY gained will be estimated
at one year. Uncertainty will be evaluated using standard
bootstrap techniques (1,000 replicates). The incremental
costs and effects will be depicted in a cost-effectiveness
analysis (CEA) plane. The resulting 'scatter plot' provides
information directly interpretable as the probability of
one intervention being cost-effective compared to the
alternative.
Statistical analysis
Data will be presented as numbers (percentage) for nom-
inal variables or means (standard deviation) for interval
variables. Differences between the two interventions will
be analysed based on intention-to-treat analysis. For inter-
val variables, differences between the two groups will be
analysed with a Students t-test, proportions will be com-
pared using the Chi-square test.
Multivariate logistic regression analysis will be used for
the development of the prediction of successful treatment
only. In literature, a wide range of patient characteristics
were considered to be associated with the outcome of
PFMT. In the Consultation on Incontinence (ICI) pro-
ceedings it was concluded that there are no reliable factors
identified yet, because the number of observations and
studies is too low.[2] However, several factors have been
identified as possible predictors of a successful outcome
after PFMT. To provide information on treatment effec-
tiveness in different subgroups of patients participating in
this trial, we will derive a prediction model and estimate
interaction of treatment effect with baseline incontinence
severity (number of leaks/week), duration of symptoms,
increasing parity, Body Mass Index, baseline pelvic floor
contraction ability, and treatment modality as factors.[2]
The defined prediction model will therefore be pre-speci-
fied resulting in less over-optimism than models in which
the choice of predictors is strongly driven by the data-set
and the need for external validation.[19] From the multi-
variate logistic model, in which success will be defined as
cure (no objective or subjective incontinence) at 12 and
18 months follow-up, we will estimate the weight of the
different coefficients. The modelling process will be inter-
nally validated by bootstrap resampling. This technique
gives an impression of how "over-optimistic" the model is
i.e., how much the performance of the model may deteri-
orate when applied to a new group of similar patients.[20]
Time plan
Patient recruitment started in March 2008 and is planned
to continue until December 2009. The follow-up period is
18 months, and therefore will continue until June 2011.
The study is conducted in cooperation with the urogynae-
cology consortium of the Netherlands. Most participating
clinics have disposition over a research nurse for follow-
up and data collection in order to fill out the web-based
case record forms.
Knowledge transfer
Outcome of the PORTRET trial will be important for
reconsidering the added value of prescribing PFMT to
every patient with stress-incontinence as primary treat-
ment, as well as comparing objective and subjective treat-
ment success or failure between TVT and PFMT. The
results of this study will be submitted to different interna-
tional and national scientific associations such as the
International Continence Society (ICS).
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